<DOC>
	<DOC>NCT01614899</DOC>
	<brief_summary>The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.</brief_summary>
	<brief_title>A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Patient meets DSMIVTR criteria for schizophrenia. Patient is aged 18 through 74 years at informed consent. Patient understands the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus. Patient has Parkinson's disease. Patient has a history or complication of malignancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>